Insulet Corp
PODD: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|#D | LOCK|h#xC& | LOCK|@Nl$JG>G |
Insulet Prepares for 2027, When New Competition Comes to Market
Business Strategy and Outlook
With little direct competition in patch pumps for two decades, Insulet has been able to convert more users, especially patients on multiple daily injections, to its innovative, tubeless insulin pump. The firm has carved a path to meaningful profitability gains.
